TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; developing the country’s health policy and working…
Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the strain on resources that genomic medicine…
Prof Dr Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) outlines the organisation’s important role within the global health landscape, how Switzerland collaborates with low- and…
Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves Switzerland’s vast array of SMEs, and why the country needs to…
PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their strategies for success in one of the world’s most innovative nations.…
Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential…
Thomas Bohn outlines how the life sciences industry in Western Switzerland has continued to perform well despite the COVID-19 pandemic, highlights some of the key recent investments in the Greater…
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination. Attractive conditions…
Pierrre Morneau of Takeda Switzerland explains the therapeutic areas at the core of the company, equitable access, the Swiss framework for rare diseases, and the major challenges he is dealing…
Alan Knox of Primex Pharmaceuticals explains how the COVID-19 pandemic has thrust the anaesthesia field back into the global spotlight, the benefits of incremental innovation in anaesthesia, and why having…
Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to market in the past four years, the road still to travel to…
In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great…
See our Cookie Privacy Policy Here
